Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.88 USD | -2.50% | +12.39% | +34.71% |
Financials (USD)
Sales 2024 * | 987M | Sales 2025 * | 1.15B | Capitalization | 6.51B |
---|---|---|---|---|---|
Net income 2024 * | 401M | Net income 2025 * | 517M | EV / Sales 2024 * | 7.81 x |
Net Debt 2024 * | 1.2B | Net Debt 2025 * | 380M | EV / Sales 2025 * | 5.97 x |
P/E ratio 2024 * |
15.9
x | P/E ratio 2025 * |
12.3
x | Employees | 373 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.89% |
Latest transcript on Halozyme Therapeutics, Inc.
1 day | -2.38% | ||
1 week | +12.63% | ||
Current month | +12.66% | ||
1 month | +14.41% | ||
3 months | +21.10% | ||
6 months | +23.20% | ||
Current year | +35.00% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 14-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 14-12-31 |
Mark Snyder
CMP | Compliance Officer | 57 | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 06-07-30 |
Chairman | 59 | 15-08-04 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 23-02-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 5 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 49.85 | -2.56% | 325 846 |
24-06-10 | 51.16 | +0.61% | 2,183,853 |
24-06-07 | 50.85 | -1.15% | 1,849,643 |
24-06-06 | 51.44 | +12.68% | 4,604,433 |
24-06-05 | 45.65 | +3.05% | 949,201 |
Delayed Quote Nasdaq, June 11, 2024 at 12:38 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.00% | 6.51B | |
+18.50% | 125B | |
+14.08% | 108B | |
-6.69% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-15.26% | 16.34B | |
+0.22% | 13.56B | |
+25.13% | 11.59B |
- Stock Market
- Equities
- HALO Stock